Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Kiniksa presents interim phase II data for rilonacept and initiates phase III RHAPSODY study

Dec. 13, 2018

MyoKardia reports phase Ib data for MYK-491

Dec. 12, 2018

Noncoding DNA affects heart risk via noncoding RNA

Dec. 12, 2018

Cation channel TRPV1 identified as a therapeutic target for cardiac hypertrophy and heart failure

Dec. 11, 2018

Targeting GPCR prevents pre-eclampsia

Dec. 7, 2018

Cytokinetics begins clinical testing of CK-3773274

Dec. 5, 2018

Enanta Pharmaceuticals discloses MAP3K5 inhibitors

Dec. 3, 2018

Morphogen-IX names clinical candidate for PAH

Nov. 30, 2018

New deep vein thrombosis model allows real-time in vivo imaging

Nov. 28, 2018

siRNA prevents pre-eclampsia in mice and primates

Nov. 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...